All In Biotech

Drug Trial Radar · NCT07838220

A Study of IBI3016 in Japanese Participants

A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Subcutaneous Administration of IBI3016 in Japanese Participants With Mild to Moderate Hypertension

Last checked: Nov 19, 2026Latest source record: Sep 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

30

Planned (sponsor's estimate)

Start

Aug 1, 2026

Primary completion

Jan 30, 2027

Study completion Nov 5, 2027

Sponsor

Sponsor type
Industry
First posted
Sep 24, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A phase I clinical study to evaluate the safety ,tolerability, pharmacokinetic and pharmocodynamic characteristics of a single subcutaneous does of IBI3016 in Japanese participants with mild to moderate hypertension.

Conditions

  • Hypertension

Interventions

  • IBI3016 Dose 4Drug

    single doses of IBI3016 administered by subcutaneous injection

  • IBI3016 Dose 3Drug

    single doses of IBI3016 administered by subcutaneous injection

  • IBI3016 Dose 2Drug

    single doses of IBI3016 administered by subcutaneous injection

  • IBI3016 Dose 1Drug

    single doses of IBI3016 administered by subcutaneous injection

  • PlaceboDrug

    single doses of IBI3016 administered by subcutaneous injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants with Adverse EventsTime frame: Through 24 weeks, up to approximately 12 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Medical Corporation Heishinkai OPHAC Hospital

    Osaka, Japan · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.